期刊文献+

非糖尿病腹膜透析患者胰岛素抵抗及脂代谢紊乱相关分析 被引量:7

Insulin resistance and dyslipidemia in non-diabetic peritoneal dialysis patients
下载PDF
导出
摘要 目的观测非糖尿病腹膜透析患者胰岛素抵抗和脂代谢紊乱发生情况及分析其相关影响因素。方法入选非糖尿病透析龄大于3个月规律连续不卧床腹膜透析(CAPD)患者48人,在相同条件下测定其身高、体重、体重指数(BMI),空腹血糖、空腹胰岛素及血脂等生化指标,以生物素-亲和素酶联免疫吸附法(ABC-ELISA)测定脂联素、瘦素、抵抗素等脂质因子。结果非糖尿病腹透患者48人(男20,女28)稳态胰岛素抵抗指数(HOMA-IR)为6.32±8.97,其中4位患者在透析过程中发展为糖尿病。根据IR中位数2.59分组,IR≥2.59组(n=24)与<2.59组(n=24)两组比较发现在BMI、三酰甘油、铁蛋白和脂联素、瘦素存在显著差异(P<0.05)。相关分析结果表明IR与铁蛋白(P<0.01)、血脂(胆固醇、三酰甘油)分别成正相关(P<0.05)。结论非糖尿病腹透患者存在胰岛素抵抗,肥胖、高三酰甘油血症、脂联素、瘦素等因素与胰岛素抵抗相关。 Objective To observe insulin resistance (IR) and dyslipidemia in non-diabetic peritoneal dialysis patients and to analyze the factors related to IR. Methods Forty-eight non-diabetic continuous ambulatory peritoneal dialysis (CAPD) patients were enrolled. Parameters including height, weight, body mass index, fast glucose, insulin and serum lipid were measured in the same situation. Leptin, adiponectin and resistin were measured by ABC-ELISA. Results The average HOMA-insu- lin resistance was 6.32± 8. 97, four of the 48 patients were progressed to diabetes. The patients were divided into two groups according to the IR medium 2. 59. There were significant differences in BMI, serum triglyceride, ferritin, adiponectin and leptin level (P〈0. 05) between these two groups. There was positive relationship between IR and ferritin (P〈0. 01), and also between serum lipid (cholesterol, triglyceride) and IR as well (P〈0. 05). Conelusions There was IR and dyslipidemia in non-diabetic PD patients, overweight, hypertriglyceridemia, adiponectin and leptin were related to IR.
出处 《复旦学报(医学版)》 CAS CSCD 北大核心 2008年第3期396-400,共5页 Fudan University Journal of Medical Sciences
关键词 胰岛素抵抗 高脂血症 脂联素 瘦素 腹膜透析 insulin resistance dyslipidemia adiponectim leptim peritoneal dialysis
  • 相关文献

参考文献17

  • 1Prinsen B,Rabelink TJ,Romijn AJ,et al.A broad-based metabolic approach to study VLDL apoB100 metabloism in patients with ESRD and patients treated with peritoneal dialysis[J].Kidney lnt,2004,65;1 064-1 075.
  • 2Chan DC,Barrett H,Watts G.F.Dyslipidemia in visceral obesity[J].Am J Cardovasc Drug,2004,4(4):227-245.
  • 3Lin SH,Lin YF,Kuo SW.Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD[J].Am J Kidney Dis,2003,42(4):774-780.
  • 4Matthews DR,Hosker JP,Rudenski AS,et al.Homeostasis model assessment:insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man[J].Diabetologia,1985,28:412-419.
  • 5Shoji T,Emoto M,Nishizawa Y.HOMA index to assess insulin resistance in renal failure patients[J].Nephron,2001,89:348-349.
  • 6中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5221
  • 7Sit D,Kadiroglu AK,Yimaz ME.The prevalence of insulin resistance and its relationship between anemia,secondary hyperparathyroidism,inflammation,and cardiac parameters in chronic hemodialysis patients[J].Renal Failure,2005,27:403-407.
  • 8Cheng SC,Chu TS,Huang KY,et al.Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD[J].Perit Dial lnt,2001,21 (3):282-289.
  • 9Shen Y,Peake WP,Kelly JJ.Should we quantify insulin resistance in patients with renal disease[J]? Nephrol,2005,10:599-605.
  • 10Alexander K,Nurit H,Ludmila L,et al.Leptin in CAPD patients:serum concentrations and peritoneal loss[J].Nephrol Dial Transplant,1999,14:400-405.

二级参考文献149

共引文献5220

同被引文献68

  • 1杨文英,杨兆军,李光伟,邢小燕.联合测量腰臀围比值(或腰围)和血压可预测代谢综合征[J].中华内分泌代谢杂志,2005,21(3):227-229. 被引量:92
  • 2Collins A J, Li S, Ma J Z, et al. Cardiovascular disease in end-stagerenal disease patients[J]. Am J Kidney Dis,2001,38(4S1):S26-29.
  • 3Tatar E, Demirci M S, Kircelli F,et al. Association of insulin resis-tance with arterial stiffness in nondiabetic peritoneal dialysis pa-tients[J].lnt Urol Nephrol,2012,44(1):255-262.
  • 4Yoo D E, Lee M J,Oh H J, et al. Low circulating adiponectin lev-els are associated with insulin resistance in non-obese peri-toneal dialysis patients[J], Endocr J,2012,59(8):685-695.
  • 5Shoji T, Emoto M, Nishizawa Y. HOMA index to assess insulin re-sistance in renal failure patients[J]. Nephron, 2001, 89(3):348-349.
  • 6Shen Y, Peake W P, Kelly J J.Should we quantify insulin resistancein patients with renal disease[J]. Nephrol,2005,10(6):599-605.
  • 7Lin S H,Lin Y F.Kuo S W.Rosiglitazone improves glucose meta-bolism in nondiabetic uremic patients on CAPD[J]. Am J KidneyDis,2003,42(4):774-780.
  • 8Matthews D R, Hosker J P, Rudenski AS, et al. Homeostasismodel assessment:insulin resistance and beta cell function fromfasting plasma glucose and insulin concentrations in man[J].Dia-betologia, 1985,28(7):412-419.
  • 9Chen Hung Yuan,Kao Tze Wah,Huang Jenq Wen.et al.Correia-tion of metabolic syndrome with residnal renal function, Solutetransport rate and peritoneal solute clearance in chronic peri-toneal dialysis patients[J].Blood Purif,2008,26⑵:138-144.
  • 10Jiang N,Qian J, Lin A,et al. Initiation of glucose-based peri-toneal dialysis is associated with increased prevalence oimetabolic syndrome in non-diabetic patients with end-stagerenal disease[J], Blood Purif,2008,26(5):423-428.

引证文献7

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部